Expression of glypican3 on pediatric malignant tumor cells and analysis of serum glypican3 levelin pediatric patients with malignant tumors
Project/Area Number |
21592274
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Pediatric surgery
|
Research Institution | 独立行政法人国立成育医療研究センター (2011) The University of Tokyo (2009-2010) |
Principal Investigator |
KANAMORI Yutaka 独立行政法人国立成育医療研究センター, 外科, 医長 (20221187)
|
Co-Investigator(Kenkyū-buntansha) |
KODAKA Tetsuro 東京大学, 医学部附属病院, 助教 (80442961)
OOTA Satoshi 東京大学, 医学系・研究科, 講師 (90324342)
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2009: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | glypican3 / 癌胎児抗原 / 胚細胞性腫瘍 / glypican 3 |
Research Abstract |
Glypican 3(GPC3) expression was investigated on the pediatric tumor cells, including neuroblastoma, nephroblastoma, rhabdomyosarcoma, germ cell tumors, and hepatoblastoma by immunohistochemistry. Neuroblastoma and rhabdomyosarcoma were negative for GPC3 but all nephroblastoma express GPC3 in varying degree. Hepatoblastoma and yolk-sac tumors and some immature teratoma also express GPC3. Serum GPC3 value could not be evaluated because there is no good system for mesuaring it now.
|
Report
(4 results)
Research Products
(7 results)